Vertex enters LOI with pan-Canadian Pharmaceutical Alliance for ALYFTREK
Vertex Pharmaceuticals signed a Letter of Intent with the pan-Canadian Pharmaceutical Alliance for ALYFTREK, a new triple combination therapy for the treatment of cystic fibrosis in patients aged 6 years and older who have at least one F508del mutation or another responsive mutation in the cystic fibrosis transmembrane conductance regulator gene. This LOI follows the positive reimbursement recommendations for ALYFTREK issued by Canada's Drug Agency in December 2025 and Institut national d'excellence en sante et services sociaux in April. With the LOI in place, Vertex will now initiate discussions with provinces and territories to support the public listing of ALYFTREK, a critical step toward making this treatment available through publicly funded drug programs across Canada.
Story updates
Vertex Pharmaceuticals signed a Letter of Intent with the pan-Canadian Pharmaceutical Alliance for ALYFTREK, a new triple combination therapy for the treatment of cystic fibrosis in patients aged 6 years and older who have at least one F508del mutation or another responsive mutation in the cystic fibrosis transmembrane conductance regulator gene.
This LOI follows the positive reimbursement recommendations for ALYFTREK issued by Canada's Drug Agency in December 2025 and Institut national d'excellence en sante et services sociaux in April.
With the LOI in place, Vertex will now initiate discussions with provinces and territories to support the public listing of ALYFTREK, a critical step toward making this treatment available through publicly funded drug programs across Canada.